Stablishment of Prevention and Treatment System for Intestinal Dysfunction

Bowel Dysfunction Clinical Trial

— A  

Official title:

The Goal-direct Treatment of Chronic Bowel Dysfunction

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04507945
• Other study ID #: Intestinal dysfunction
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: October 1, 2020
• Est. completion date: September 30, 2023

Study information

• Verified date: August 2020
• Source: Nanjing University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dysfunction and intestinal endocrine dysfunction. This project will use genomics, metabonomics, microbiome and other omics techniques to study the clinical pathway of CID integrated therapy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 50
• Est. completion date: September 30, 2023
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The Patients with chronic bowel dysfunction

Exclusion Criteria:

• Past severe underlying diseases of the respiratory system and cardiovascular system,

• Allergy to treatment-related drugs,

• Pregnancy,

• Accept CID surgery.

Related Conditions & MeSH terms

• Bowel Dysfunction
• Intestinal Diseases

Intervention

Drug:
• Nutritional Therapy, Metabolic Disorder, Regular
According to the result reported by Byrne, Wilmore, etc. in 1992 ~ 1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing University School of Medicine

References & Publications (2)

He D, Wang S, Hu H, Yin HY. [Advances in the research of protective effect of curcumin on intestinal mucosal barrier function]. Zhonghua Shao Shang Za Zhi. 2019 Feb 20;35(2):157-160. doi: 10.3760/cma.j.issn.1009-2587.2019.02.013. Review. Chinese. — View Citation

Pironi L, Corcos O, Forbes A, Holst M, Joly F, Jonkers C, Klek S, Lal S, Blaser AR, Rollins KE, Sasdelli AS, Shaffer J, Van Gossum A, Wanten G, Zanfi C, Lobo DN; ESPEN Acute and Chronic Intestinal Failure Special Interest Groups. Intestinal failure in adults: Recommendations from the ESPEN expert groups. Clin Nutr. 2018 Dec;37(6 Pt A):1798-1809. doi: 10.1016/j.clnu.2018.07.036. Epub 2018 Aug 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	nutrition index		3 years